^
BIOMARKER:

HER-2 positive

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
HER-2 positive
HER2 Positive Breast Cancer
ARX788
Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 3 days - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
tislelizumab + ZW25
Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
HER-2 positive
Gastric Cancer
tislelizumab + ZW25
Sensitive: C3 – Early Trials
ASCO 2022 - 3 days - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
Mol Cancer Ther - 3 weeks - (New D)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
FDA - 3 weeks - (New A1)
HER-2 positive
HER2 Positive Breast Cancer
HM 78136B
Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
tucatinib
Sensitive: C2 – Inclusion Criteria
Mol Cancer Ther - 3 weeks - (New D)
HER-2 positive
HER2 Positive Breast Cancer
nivolumab + fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
HER-2 positive
Ovarian Cancer
EDIT-202
Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
HER-2 positive
CRC
trastuzumab + pertuzumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
trastuzumab
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
TCHP
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
TCH
Sensitive: A2 - Guideline
HER-2 positive
Gastroesophageal Cancer
trastuzumab
Sensitive: A2 - Guideline
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
HER-2 positive
Endometrial Cancer
trastuzumab
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
HER2 inhibitor
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
AC-TH
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
lapatinib
Sensitive: A2 - Guideline
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER2 inhibitor
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
AC-THP
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
TH
Sensitive: A2 - Guideline
HER-2 positive
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
pyrotinib
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pyrotinib
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
Gastric Cancer
trastuzumab + pertuzumab
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine + pertuzumab
Sensitive: B - Late Trials
HER-2 positive
Urothelial Cancer
disitamab vedotin
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
Gastric Cancer
nivolumab
Resistant: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
SYD985
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
TX05 (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
EG12014 (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Sensitive: B - Late Trials
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: B - Late Trials
HER-2 positive
Gastric Cancer
ramucirumab
Sensitive: B - Late Trials
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
CYNK-101
Sensitive: B - Late Trials
HER-2 positive
Gastric Cancer
CYNK-101
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Hervelous (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
Small Cell Lung Cancer
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
NSCLC
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
HER-2 positive
Gastroesophageal Cancer
pembrolizumab + trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Colon Cancer
ado-trastuzumab emtansine
Sensitive: C1 - Off-label
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
HER-2 positive
Solid Tumor
neratinib
Resistant: C1 - Off-label
HER-2 positive
Gastric Cancer
ado-trastuzumab emtansine
Sensitive: C1 - Off-label
HER-2 positive
Esophageal Squamous Cell Carcinoma
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Biliary Tract Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: C1 - Off-label
HER-2 positive
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
HER-2 positive
NSCLC
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
HER-2 positive
CRC
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Gastric Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: C1 - Off-label
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
paclitaxel
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Lung Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
margetuximab + MGD013
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
PRS-343
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
PRS-343
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
PRS-343
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
nivolumab + trastuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
paclitaxel
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Adenocarcinoma
pembrolizumab + margetuximab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Solid Tumor
KN046 + KN026
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine + neratinib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
CRC
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
pyrotinib + SHR6390
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastroesophageal Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
afatinib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
A166
Sensitive: C2 – Inclusion Criteria
HER-2 positive
CRC
A166
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
KN026
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
disitamab vedotin
Sensitive: C2 – Inclusion Criteria